Loading
Obesity / Overweight / LY4086940 · Phase 1 Trial
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 registry record for LY4086940, a novel agent, with enrollment completed but no results posted. The study was designed to characterize safety, tolerability, and pharmacokinetics in healthy volunteers and cohorts with overweight, obesity, and type 2 diabetes, but clinical outcomes and efficacy data are not yet available.
Phase 1, Interventional, Randomized, Parallel, Double masking, Basic Science purpose. Healthy, Overweight, Obesity, Type 2 Diabetes; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: Part A: LY4086940 Single Dose (Healthy Participants); Part A: LY4086940 Multiple Dose (Healthy Participants); Part B: LY4086940 Multiple Dose (Participants with Overweig…; Part C: LY4086940 Multiple Dose (Japanese/Chinese Participa…; Part…. Compared with: Part A: Placebo Single Dose (Healthy Participants) — Placebo Comparator; Part A: Placebo Multiple Dose (Healthy Participants) — Placebo Comparator; Part B: Placebo Multiple Dose (Participants with Overweight… — Placebo Comparator; Part C:…. n = 219. 5 sites: United States, Singapore.
This is a Phase 1 registry record for LY4086940, a novel agent, with enrollment completed but no results posted. The study was designed to characterize safety, tolerability, and pharmacokinetics in healthy volunteers and cohorts with overweight, obesity, and type 2 diabetes, but clinical outcomes and efficacy data are not yet available.
No safety or tolerability results are reported in this registry record; recruitment completion does not imply data are available. No efficacy, biomarker, or clinical outcomes are described; the study is limited to characterizing safety and drug processing.
This early-phase study cannot yet inform clinical practice. Results when posted will establish preliminary safety signals and pharmacokinetic properties necessary for progression to efficacy trials.
Phase 1 safety and tolerability study with completed enrollment but no results reported; early-stage characterization of a novel agent with no efficacy data.
As stated by the source record.
Quoted from the source exactly as published.
This early-phase study cannot yet inform clinical practice. Results when posted will establish preliminary safety signals and pharmacokinetic properties necessary for progression to efficacy trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06945419). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: COMPLETED. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 219 participants (ACTUAL). Conditions: Healthy, Overweight, Obesity, Type 2 Diabetes. Interventions: DRUG: LY4086940; DRUG: Placebo; DRUG: LY4086940. Primary outcome measures: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration , Baseline up to Week 9. Brief summary: The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.